Zomedica Appoints Two Animal Health Veterans to Board of Directors
ANN ARBOR, Mich., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM), a veterinary pharmaceutical company, today announced it has appointed Jane Eagleson and Tom Robitaille to its Board of Directors, effective immediately. These appointments expand the Board to eight directors, five of whom are independent.
"Together, Jane and Tom bring a combined 60 years of global animal health experience to our Board of Directors," stated Chairman and CEO Gerald Solensky Jr. "The addition of these two independent directors ensures Zomedica will continue to benefit from diverse but complementary perspectives, skills and insights as we continue to build the business."
A veterinarian with more than 30 years of experience in animal health pharmaceutical development, Eagleson is currently Vice President of Clinical and Regulatory Affairs at Nexvet Biopharma (Nasdaq:NVET), a veterinary biotherapeutics company. She concurrently serves, since January 2013, as owner of Bleecker Street Consulting, an animal health consulting firm that specializes in pharmaceutical development strategy in North America, Europe and the Oceania markets.
From September 2007 through December 2012, Eagleson held various leadership positions with Argenta, a pharmaceutical contract research and contract manufacturing organization. She joined Argenta as Head of Clinical Research and Development and elevated to Head of Growth Strategies where she assumed overall ownership of the company's strategic plan.
Prior to that, Eagleson served in several senior director roles with Pfizer, Inc. from December 1999 through February 2007, leaving the company as Senior Director of Asian Business Development where she was based in India and responsible for strategic planning and execution of Asian business initiatives for both animal health and human health organizations.
Before Pfizer, Eagleson was a Director with Merial from 1991 to 1997 and served as Research Veterinarian with Merck Animal Health from 1985 to 1991. She has a Master of Veterinary Science in immunology from Massey University and Bachelor of Veterinary Science (U.S. doctor of veterinary medicine equivalent) from the University of Sydney. She has also authored more than 35 publications in peer reviewed journals.
A results-focused international business leader with 30 years of animal health experience, Robitaille is currently Vice President of Veterinary Channel Development at Blue Buffalo Company (Nasdaq:BUFF), a premium, all-natural pet food company.
Prior to that, Robitaille held various director level and senior management positions during his 19-year career with the animal health pharmaceutical company Vetoquinol SA Inc. Robitaille was the Americas Group Director from September 2006 through October 2015, where he managed affiliates and regional distributors in Canada, USA, Mexico and Brazil. From October 2004 to October 2006 he was responsible for veterinary pharmaceutical operations in the United Kingdom, Ireland, Belgium, and the Netherlands as Managing Director. He also served as Director of International Development from October 2001 through September 2004, where he contributed to an increase in sales and profit in Eastern Europe, Asia Pacific, Africa, and Latin America.
Before Vetoquinol, Robitaille was a Product Manager with Elanco, the animal health division of Eli Lilly and Company, and prior thereto, started his animal health career serving in various sales and marketing positions throughout Canada, USA, Europe and the Middle East with Sandoz, a generic pharmaceuticals company. Robitaille has a Master of Business Administration from the University of Warwick and Bachelor of Science degree from Concordia University.
With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical company targeting health and wellness solutions for companion animals (canine, feline and equine) through a ground-breaking approach that focuses on the unmet needs of clinical veterinarians. Zomedica is building a diversified portfolio of products comprised of the discovery, development and commercialization of innovative drugs alongside novel drug delivery systems, devices and diagnostics. With multiple clinical veterinarians in executive management, it is Zomedica's mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
- Email Alerts: sign up for investor, product and service alerts at www.ZOMEDICA.com
- LinkedIn: www.linkedin.com/company/zomedica
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Zomedica Investor Relations Contact Shameze Rampertab, CPA, CA firstname.lastname@example.org +1 647.283.3630 Zomedica Media Contact Andrea Eberle email@example.com +1 734.369.2555